HSD-1 inhibitor SPI-62

{
  "id": "MLC-T-ONC-014198",
  "term": "HSD-1 inhibitor SPI-62",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable selective inhibitor of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1; 11bHSD1; HSD11B1; HSD1; HSD-1), with potential protective activity for disorders of corticosteroid excess. Upon oral administration, HSD-1 inhibitor SPI-62 selectively binds to and inhibits the activity of HSD-1. This prevents the conversion of cortisone to the active hormone cortisol and thereby preventing the activation of the glucocorticoid receptors (GRs). By blocking cortisol production in metabolic tissues, SPI-62 may inhibit the adverse metabolic effects that are caused by exogenous administration of glucocorticoids or in disorders in which cortisol is secreted in excess. HSD-1 is highly expressed in metabolic tissues, such as liver, skeletal muscle, and adipose tissue. It plays a crucial role in regulating the production of cortisol to activate the GRs.",
  "synonyms": [
    "11beta-hydroxysteroid dehydrogenase type 1 inhibitor SPI-62"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/hsd-1-inhibitor-spi-62/"
}